D-Amphetamine in obsessive-compulsive disorder
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
In a double-blind crossover study, single doses of d-amphetamine and placebo were administered to 12 patients with severe chronic obsessive-compulsive disorder (OCD). Improvement of obsessional symptoms was significant on clinical ratings and was correlated with improved performance on an attention task. Changes were also significant for self-rated measures of activation and altered reality. The behavior response to amphetamine was not statistically correlated with subsequent improvement during a 6-week clomipramine trial, although the direction of change was the same during both treatments for every patient studied.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although three small clinical trials have shown evidence that the related drug, dexamphetamine, can be effective in OCD (Insel et al. 1983; Joffe et al. 1991; Koran et al. 2009).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Insel et al. 1983
Citations
Cites
A continuous performance test of brain damage
Rosvold, H. E., Mirsky, A. F., Sarason, I., Bransome, E. D., & Beck, L. H. (1956) · Journal of Consulting Psychology · doi:10.1037/h0043220 · Cited by 2,261 · cited 1×
“Attention was measured by a modification of Rosvold's continuous performance task (Rosvold et al. 1956).”
MethodGawin, F. H., & Ellinwood, E. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805053181806 · Cited by 965
Stereotyped activities produced by amphetamine in several animal species and man
Randrup, A., & Munkvad, I. (1967) · Psychopharmacologia · doi:10.1007/bf00404607 · Cited by 613 · cited 1×
“Reports in humans and other primates (Wallach 1974; Randrup and Munkvad 1967; Schi6rring 1975) have described amphetamine-induced stereotyped behaviors that superficially resemble compulsive symptoms, including cleaning and checking rituals which may be accompanied by a subjective sense of compulsion.”
BackgroundClomipramine Treatment of Obsessive-Compulsive Disorder: I. A Controlled Clinical Trial
Thorén, P. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780240079009 · Cited by 497
Clomipramine and Exposure for Obsessive-Compulsive Rituals: 1
Marks, I. M., Stern, R. S., Mawson, D., Cobb, J., & McDonald, R. (1980) · British Journal of Psychiatry · doi:10.1192/bjp.136.1.1 · Cited by 448 · cited 1×
“First, some patients with the disorder have recently been found to improve with the tricyclic antidepressant clomipramine (Thoren et al. 1980; Marks et al. 1980; Insel et al. 1982).”
BackgroundNeuropsychopharmacology of monoamines and their regulatory enzymes.
Ma, L. (1974) · PubMed · Cited by 415
Obsessive-Compulsive Disorder: A Double-blind Trial of Clomipramine and Clorgyline
Insel, T. R. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.04390010015002 · Cited by 343
Self-citationAMPHETAMINE PSYCHOSIS: I. DESCRIPTION OF THE INDIVIDUALS AND PROCESS
ELLINWOOD, E. H. (1967) · The Journal of NERVOUS and MENTAL DISEASE · doi:10.1097/00005053-196704000-00005 · Cited by 285
Randrup, A., & Br�strup, C. (1977) · Psychopharmacology · doi:10.1007/bf00492370 · Cited by 263 · cited 1×
“Finally, clomipramine, which has been singled out as particularly effective for OCD (Insel and Murphy 1981 for review), is distinguished among tricyclics as a powerful blocker of DA uptake (Randrup and Braestrup 1977).”
BackgroundVan Kammen, D. P., & Murphy, D. L. (1975) · Psychopharmacologia · doi:10.1007/bf00428897 · Cited by 237 · cited 2×
“A large variance in the affective response to amphetamine has been previously reported in normal subjects (Tecce and Cole 1974; Brown et al. 1978), depressives ( Van Kammen and Murphy 1975; Silberman et al. 1981; Nurnberger et al. 1982), and schizophrenics (Van Kammen et al. 1982).”
BackgroundMethodSelf-citation
Research works printed but not linked: 2
- Insel TR, Alterman I, Murphy DL (1982) Antidepressant and antiobsessional effects with clomipramine. Psychopharmacol Bull 18: 315?319
- Murphy DL, Pickar D, Alterman IS (1982) Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EI, Sudilovsky A, Gershon S (eds) The behavior of psychiatric patients. Marcel Dekker, New York, pp 355?392
Cited by
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Baxter, L. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800150017003 · Cited by 860
Obsessive-Compulsive Disorder: A Double-blind Trial of Clomipramine and Clorgyline
Insel, T. R. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.04390010015002 · Cited by 343
Self-citationDrug Treatment of Canine Acral Lick: An Animal Model of Obsessive-compulsive Disorder
Rapoport, J. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070011002 · Cited by 212
Fineberg, N. A., Apergis-Schoute, A. M., Vaghi, M. M., Banca, P., Gillan, C. M., Voon, V., Chamberlain, S. R., Cinosi, E., Reid, J., Shahper, S., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx088 · Cited by 183
The Use of Psychostimulants in General Psychiatry: A Reconsideration
Chiarello, R. J. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800150110013 · Cited by 184
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
“In two double-blind, placebo controlled studies, d-amphetamine was superior to placebo in un-medicated OCD adults (Insel et al., 1983; Joffe et al., 1991).”
BackgroundFineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
“A randomized placebo-controlled trial of single dose d-amphetamine produced short-lived benefits (Insel et al., 1983a), while another randomized controlled trial comparing d-amphetamine and caffeine intriguingly noted that both compounds were associated with rapid improvement of obsessive…”
BackgroundMethodChristensen, H. M., Hadži-Pavlović, D., Andrews, G., & Mattick, R. P. (1987) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.55.5.701 · Cited by 162
Cerebrospinal Fluid Neurochemistry in Children and Adolescents With Obsessive-Compulsive Disorder
Swedo, S. E. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820010029004 · Cited by 150
Drug treatment of obsessive-compulsive disorder
Kellner, M. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.2/mkellner · Cited by 145
Assessment of Severity and Change in Obsessive Compulsive Disorder
Goodman, W. K., & Price, L. H. (1992) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30214-4 · Cited by 128
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Animal models of compulsive behavior
Pitman, R. K. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90022-x · Cited by 117
Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder
Abudy, A., Juven‐Wetzler, A., & Zohar, J. (2011) · CNS Drugs · doi:10.2165/11587860-000000000-00000 · Cited by 119
“Two small, double-blind, placebo-controlled studies([85,86]) found a single dose of dextroamfetamine 30mg to be clearly superior to placebo in relieving symptoms of OCD.”
BackgroundKolada, J. L., Bland, R. C., & Newman, S. C. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05788.x · Cited by 103
Rubín, R. T., Ananth, J., Villanueva‐Meyer, J., Trajmar, P. G., & Mena, I. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00305-m · Cited by 93
Treatment-resistant OCD: Pharmacotherapies in adults
van Roessel, P. J., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Van Ameringen, M., & Rodríguez, C. I. (2023) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152352 · Cited by 86
Zike, I. D., Xu, T., Hong, N., & Veenstra-VanderWeele, J. M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.09.012 · Cited by 87
“On the other hand, stimulants do not appear to be a common cause of worsening in OCD patients themselves and may even lead to improvements in some patients (Insel et al., 1983).”
BackgroundTranslational approaches to obsessive‐compulsive disorder: from animal models to clinical treatment
Fineberg, N., Chamberlain, Sr., Hollander, E., Boulougouris, V, & Robbins, T. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01422.x · Cited by 82
Marks, I., & O'Sullivan, G. (1988) · British Journal of Psychiatry · doi:10.1192/bjp.153.5.650 · Cited by 81
Joel, D., & Doljansky, J. T. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300010 · Cited by 79
“…encephalitis; Jelliffe, 1932), changes in obsessive–compulsive symptoms following the administration of amphetamine and cocaine to OCD patients (Insel et al, 1983; Leonard and Rapoport, 1987; McDougle et al, 1989), the surplus therapeutic benefits obtained with coadministration of SRIs and…”
BackgroundInfluentialPsychostimulants in supportive care
Homsi, J., Walsh, D., & Nelson, K. A. (2000) · Supportive Care in Cancer · doi:10.1007/s005200050007 · Cited by 75
Obsessive-compulsive disorder: Is there a frontal lobe dysfunction?
Khanna, S. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90171-0 · Cited by 64
The neuroethological approach to obsessive-compulsive disorder
Stein, D. J., Shoulberg, N., Helton, K., & Hollander, E. (1992) · Comprehensive Psychiatry · doi:10.1016/0010-440x(92)90053-s · Cited by 63
Pharmacological Treatment of Obsessive-Compulsive Disorder
Simpson, H. B. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_12 · Cited by 59
Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder
Austin, L. S., Lydiard, R. B., Ballenger, J. C., Cohen, B. M., Laraia, M. T., Zealberg, J. J., Fossey, M. D., & Ellinwood, E. H. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90107-w · Cited by 63
Murray, G. K., Knolle, F., Ersche, K. D., Craig, K. J., Abbott, S., Shabbir, S. S., Fineberg, N. A., Suckling, J., Sahakian, B. J., Bullmore, E. T., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05292-2 · Cited by 53
Neuroendocrine and behavioral responses to mCPP in Obsessive–Compulsive Disorder
Khanna, S. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(00)00048-2 · Cited by 56
Schilman, E. A., Klavir, O., Winter, C., Sohr, R., & Joel, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.208 · Cited by 64
Rating Scales for Obsessive Compulsive Disorder
Kim, S. W., Dysken, M. W., & Katz, R. J. (1989) · Psychiatric Annals · doi:10.3928/0048-5713-19890201-07 · Cited by 54
Psychostimulants for depression
Candy, B., Jones, L., Williams, R., Tookman, A., & King, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006722.pub2 · Cited by 156
Neurobiology of Childhood Obsessive-Compulsive Disorder
Fitzgerald, K. D., MacMaster, F. P., Paulson, L. A. D., & Rosenberg, D. R. (1999) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/s1056-4993(18)30168-8 · Cited by 54
Cross-species models of OCD spectrum disorders
Boulougouris, V., Chamberlain, S. R., & Robbins, T. W. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.07.016 · Cited by 50
“For example, D-amphetamine has actually been shown to ameliorate OCD symptoms in certain circumstances (Insel et al., 1983).”
Obsessive-compulsive disorder.
March, J. S., Johnston, H., & Greist, J. H. (1989) · PubMed · Cited by 49
Pharmacologic Treatment of Obsessive Compulsive Disorders *
Jenike, M. A. (1992) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30217-x · Cited by 48
Psychostimulants in Psychiatry
Warneke, L. B. (1990) · The Canadian Journal of Psychiatry · doi:10.1177/070674379003500102 · Cited by 50
Brambilla, F., Bellodi, L., Perna, G., Arancio, C., & Bertani, A. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00549-5 · Cited by 46
Cardiovascular safety of calcium, magnesium and strontium: what does the evidence say?
Curtis, E., Cooper, C. C., & Harvey, N. C. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01799-x · Cited by 45
Treatment-refractory obsessive compulsive disorder
Atmaca, M. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.12.004 · Cited by 44
“Dextroamphetamine, a psychostimulant drug was showed to be beneficial as monotherapy in OCD treatment (Insel et al., 1983; Joffe et al., 1991).”
BackgroundDifferent Views of Anxiety Disorders
Selek, S. (2011) · InTech eBooks · doi:10.5772/1022 · Cited by 39
An analysis of the high psychotropic off-label use in psychiatric disorders
Devulapalli, K. K., & Nasrallah, H. A. (2009) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2009.01.005 · Cited by 42
“Obsessive Compulsive Disorder is the only DSM-IV classified disorder for which stimulants may be used off-label (Insel et al., 1983).”
BackgroundKumar, P., & Rai, V. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00495-0 · Cited by 38
Medical Use of Psychostimulants: An Overview
Holmes, V. F. (1995) · The International Journal of Psychiatry in Medicine · doi:10.2190/2tvt-2lh0-ad5a-cp91 · Cited by 29
Melo-Felippe, F. B., Andrade, J. B. D. S., Giori, I. G., Vieira-Fonseca, T., Fontenelle, L. F., & Kohlrausch, F. B. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0697-0 · Cited by 30
“…(McDougle et al. 1994; Sasson and Zohar 1996; Saxena et al. 1996; Hollander et al. 2003; Bystritsky et al. 2004; Carey et al. 2005; Komossa et al. 2010) and an exacerbation of OCD symptoms during administration of amphetamine or cocaine to OCD patients (Insel et al. 1983; Crum and Anthony 1993).”
BackgroundDexamphetamine for Obsessive-Compulsive Disorder
WOOLLEY, J. B., & HEYMAN, I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.183 · Cited by 24
The Pharmacological Treatment of Obsessive-Compulsive Disorders
Jenike, M. A. (1990) · International Review of Psychiatry · doi:10.3109/09540269009026610 · Cited by 24
Golubchik, P., Sever, J. M., Weizman, A., & Zalsman, G. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31821f4da9 · Cited by 27
“Two small, doubleblind, placebo-controlled, single-dose, crossover studies found d-amphetamine clearly superior to placebo in relieving symptoms of OCD.(31,32) Recently, a 5-week, double-blind, caffeinecontrolled study found a reduction in OCD symptoms after d-amphetamine addition to SSRIs or serotonin-norepinephrine…”
BackgroundMEDICAL AND SURGICAL TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
Rapoport, J. L., & Inoff‐Germain, G. (1997) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70323-6 · Cited by 24
Pharmacotherapy of Obsessive‐Compulsive Disorder
Jermain, D. M., & Crismon, M. L. (1990) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1990.tb02574.x · Cited by 21
Obsessive-Compulsive Disorder: Diagnosis, Epidemiology, Etiology, and Treatment
Sassano-Higgins, S. A., & Pato, M. T. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130211 · Cited by 26
Effects of fenfluramine on plasma HVA in OCD
Hollander, E., Stein, D. J., Saoud, J. B., DeCaria, C. M., Cooper, T. B., Trungold, S., Stanley, M., & Liebowitz, M. R. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90081-d · Cited by 20
Zohar, J., Greenberg, B. D., & Denys, D. A. J. P. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00021-8 · Cited by 22
Recent Advances in the Psychopharmacological Treatment of Anxiety Disorders
Lydiard, R. B., Roy‐Byrne, P., & Ballenger, J. C. (1988) · Psychiatric Services · doi:10.1176/ps.39.11.1157 · Cited by 19
Owley, T. B., Owley, S., LEVENTHAL, B. L., & Cook, E. H. (2002) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454602760219207 · Cited by 16
“In a double-blind, placebo-controlled, counterbalanced study, Insel et al. (1983) gave dextroamphetamine to 11 OCD patients and found significant decreases (on both self-and observer ratings) in obsessions and compulsions in 10 of these subjects.”
Somatic treatments for obsessive-compulsive disorders
Jenike, M. A., Baer, L., & Minichiello, W. E. (1987) · Comprehensive Psychiatry · doi:10.1016/0010-440x(87)90032-0 · Cited by 16
Advances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Longhurst, J. G., Carpenter, L. L., Epperson, C. N., Price, L. H., & McDougle, C. J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00019-0 · Cited by 13
Eye-tracking, attention and amphetamine challenge
Siever, L. J., Insel, T. R., Hamilton, J. A., Nürnberger, J. I., Alterman, I., & Murphy, D. L. (1987) · Journal of Psychiatric Research · doi:10.1016/0022-3956(87)90013-6 · Cited by 13
Self-citationGender differences in antidepressant and activating drug effects on self-perceptions
Hamilton, J. A., Alagna, S. W., & Pinkel, S. (1984) · Journal of Affective Disorders · doi:10.1016/0165-0327(84)90044-2 · Cited by 11
Self-citationBerlin, H. A., Hamilton, H., & Hollander, E. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20045 · Cited by 12
OCD and transvestism: is there a relationship?
Abdo, C. H. N., Hounie, A. G., Scanavino, M. D. T., & Miguel, E. C. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00294.x · Cited by 11
Obsessive-Compulsive Disorder: An Update for the Clinician
Koran, L. M. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.3.foc299 · Cited by 13
Ameringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 14
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research
Koran, L. M., & Aboujaoude, E. N. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170526120916 · Cited by 10
Delorme, R., Betancur, C., Chaste, P., Kernéis, S., Stopin, A., Mouren, M., Collet, C., Bourgeron, T., Leboyer, M., & Launay, J. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31016 · Cited by 9
“These include the high incidence of OC behavior in a number of basal-ganglia-related disorders, such as Tourette syndrome [Grados and Mathews, 2008], changes in OC symptoms following the administration of the dopamine reuptake inhibitor amphetamine to OCD patients [Insel et al., 1983], and the therapeutic benefits obt…”
BackgroundInfluentialAnxiety levels and related pharmacological drug treatment: a memorandum for the third millennium.
Pasquini, M., & Berardelli, I. (2009) · PubMed · Cited by 7
Behavioral responses to a dopaminergic challenge in obsessive-compulsive disorder
Lemus, C. Z., Robinson, D. G., Kronig, M. H., Cole, K., & Lieberman, J. A. (1991) · Journal of Anxiety Disorders · doi:10.1016/0887-6185(91)90036-s · Cited by 6
Biological challenges in obsessive compulsive disorder
Swinson, R. P., & Joffe, R. T. (1988) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(88)90044-9 · Cited by 5
Drug Treatment of Phobias: Efficacy and Optimum Use
Levin, A. P., & Liebowitz, M. R. (1987) · Drugs · doi:10.2165/00003495-198734040-00004 · Cited by 5
“There is also anecdotal evidence that amphetamines may alleviate obsessive-compulsive symptoms (Insel et al. 1983).”
BackgroundGautam, M. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001716 · Cited by 5
“These were not included because of a lack of at least 2 RCTs analyzing them as augmentation agents (methylphenidate, amphetamine, mirtazapine, and clomipramine).(18,61,68,69) Although ondansetron and celecoxib showed positive results, multiple confounders across all trials limit the availability of data to assess them…”
BackgroundPharmacologie Expérimentale et Clinique des Psychostimulants
Bourin, M., Mellédo, J. L., & Malinge, M. (1995) · The Canadian Journal of Psychiatry · doi:10.1177/070674379504000707 · Cited by 6
Quantifying free behaviour in an open field using k-motif approach
Könings, M., Blokpoel, M., Kapusta, K., Claassen, T., Buitelaar, J. K., Glennon, J. C., & Bielczyk, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-56482-z · Cited by 4
Approaches to Treatment Resistance
Pallanti, S., Grassi, G., & Cantisani, A. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch5 · Cited by 1
Pharmacotherapy of Obsessive‐Compulsive Disorder
Decloedt, E., & Stein, D. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch2 · Cited by 1
Modelos experimentais para o estudo do transtorno obsessivo compulsivo: perspectivas e limitações
Raminelli, A. O. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2021.tde-10052021-142439 · Cited by 4
Park-Oates, M., & Prus, A. J. (2023) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000723 · Cited by 1
“Clinical studies also have found amphetamine to reduce compulsive behavior in obsessive-compulsive disorder and impulsive behavior in attention deficit hyperactivity disorder (Insel et al., 1983; Joffe et al., 1991; Fineberg et al., 2020; Arkell et al., 2022), and these therapeutic effects may be reflected by reductio…”
BackgroundHanau, M. S., & Jenike, E. A. (2012) · Current psychiatry · Cited by 1
Sachdev, R. A., Ruparelia, R., Reid, J. E., Mpavenda, D., Cinosi, E., & Fineberg, N. A. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.016 · Cited by 2
The Treatment of Obsessive-Compulsive Disorder and the Approaches to Treatment Resistance
Pallanti, S., Grassi, G., & Cantisani, A. (2011) · InTech eBooks · doi:10.5772/21517 · Cited by 3
“conducted before the introduction of SSRI for OCD treatment (Insel et al., 1983; Joffe et al., 1991).”
BackgroundMaina, G., Pessina, E., Asinari, G. F., Micari, J., & Bogetto, F. (2007) · Institutional Research Information System University of Turin (University of Turin) · Cited by 1
Veale, D. M. (1995) · UCL Discovery (University College London) · Cited by 1
Dopamine and obsessive disorder: a clinical study with cck and methyl phenidate.
Ananth, J., Muffaoue, K., & Poland, R. E. (1992) · PubMed Central
Treatments for Obsessive-Compulsive Disorder and Comorbid Disorders
Ivarsson, T., & Weidle, B. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108235655.022
(2007) · Elsevier eBooks · doi:10.1016/b978-2-294-70195-5.50010-4
Chapter 52. Treatment of Obsessive-Compulsive Disorder
Kayser, R. R., & Simpson, H. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as52 · Cited by 1
Behandlung bei psychischer und körperlicher Komorbidität
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_11
Treatment of anxiety: current status and controversial issues
Simpson, H. B., Neria, Y., Lewis‐Fernández, R., & Schneier, F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.024
Metadata
- Authors
- Insel, T. R., Hamilton, J. A., Guttmacher, L. B., & Murphy, D. L.
- Affiliations
- National Institutes of Health (US)
- Venue
- Psychopharmacology
- Published
- 1983-06
- Volume
- 80
- Issue
- 3
- Pages
- 231-235
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1984000803
- Cited by
- 90
- References
- 39
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 4 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 4 · 2012: 4
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- d-amphetamine, obsessive-compulsive disorder, obsessive-compulsive symptoms, attentional performance, altered reality, clomipramine, stimulant medication, placebo response
- MeSH terms
- Adolescent, Adult, Dextroamphetamine, Double-Blind Method, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Psychiatric Status Rating Scales
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.